



## Trend of OPDIVO

# Sales Trend of OPDIVO by Each Cancer




# Number of Patients Newly Prescribed with OPDIVO by Each Cancer (Estimation)



Source: Estimation from external and internal data


# Trend of total sales of ICPIs and OPDIVO share



Source: External data


# Number of GC\* Patients per year in Japan

\* : Unresectable Advanced or Recurrent GC



Estimation based on internal survey (2020)

# Prescription Ratio in Patients Newly Treated\* for 1L GC




\*Patients starting treatment within the last 3 month

Source: External data (Nov 2021~Apr 2024: n=200~204)


# Number of ESC\* Patients per year in Japan

\* : Unresectable Advanced or Recurrent ESC



Estimation based on internal survey (2022)

# Prescription Ratio in Patients Newly Treated\* for 1L ESC(Squamous Cell Carcinoma)




\*Patients starting treatment within the last 3 month

Source: External data (May 2022~Apr 2024: n=150~155)




# Number of ESC(Perioperative)Patients per year in Japan



Estimation based on internal survey (2022)

# Prescription Ratio in Patients Newly Treated\* for ESC(adjuvant chemotherapy)




\*Patients starting treatment within the last 3 months

Source: External data (Mar 2022~Jun 2024 n=130~152)

# Number of NSCLC\* Patients per year in Japan


\* Unresectable Advanced or Recurrent NSCLC

1L



Estimation based on internal survey (2021)

# Prescription Ratio in Patients Newly Treated\* for 1L NSCLC




(Before approval)

\*Patients starting treatment within the last 1 month (Except Driver Mutation)


Source: External data (Nov 2020~May 2024: n=167~245)

# Number of Bladder Cancer(Perioperative)Patients per year in Japan



Estimation based on internal survey (2022)

# Prescription Ratio in Patients Newly Treated\* for Bladder Cancer (adjuvant chemotherapy)




\*Patients starting treatment within the last 3 months

Source: External data (Jan 2022~Apr 2024: n=200)

# Number of RCC\* Patients per year in Japan




\* : Unresectable or Metastatic RCC



Estimation based on internal survey (2022)

# Prescription Ratio in Patients Newly Treated\* for 1L RCC



\*Patients starting treatment within the last 3 months

Source: External data (Sep 2018~Apr 2024: n=46~150)